We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi–Trace Element Products.
- Authors
Vanek, Vincent W.; Borum, Peggy; Buchman, Alan; Fessler, Theresa A.; Howard, Lyn; Jeejeebhoy, Khursheed; Kochevar, Marty; Shenkin, Alan; Valentine, Christina J.
- Abstract
The parenteral multivitamin preparations that are commercially available in the United States (U.S.) meet the requirements for most patients who receive parenteral nutrition (PN). However, a separate parenteral vitamin D preparation (cholecalciferol or ergocalciferol) should be made available for treatment of patients with vitamin D deficiency unresponsive to oral vitamin D supplementation. Carnitine is commercially available and should be routinely added to neonatal PN formulations. Choline should also be routinely added to adult and pediatric PN formulations; however, a commercially available parenteral product needs to be developed. The parenteral multi–trace element (TE) preparations that are commercially available in the U.S. require significant modifications. Single-entity trace element products can be used to meet individual patient needs when the multiple-element products are inappropriate (see Summary/A.S.P.E.N. Recommendations section for details of these proposed modifications).
- Subjects
VITAMIN deficiency; VITAMIN D deficiency; PARENTERAL solutions; CARNITINE; CHOLINE; CHROMIUM; COPPER; DIETARY supplements; DRUG toxicity; FLUORIDES; IODIDES; IRON; MANGANESE; NUTRITIONAL requirements; SELENIUM; TRACE elements; VITAMIN D; VITAMINS; ZINC; CHOLECALCIFEROL; AMERICAN Society for Parenteral &; Enteral Nutrition; STANDARDS; THERAPEUTICS
- Publication
Nutrition in Clinical Practice, 2012, Vol 27, Issue 4, p440
- ISSN
0884-5336
- Publication type
Article
- DOI
10.1177/0884533612446706